Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Inclusion Criteria: * Patients with chronic myeloid leukemia; * Age: 18-65 years,gender:both. * Weight: standard weight ± 20% within, and avoid weight disparity is too large; * No previous radiation therapy, chemotherapy, or surgery within 1 weeks before treatment with imatinib; * Performance status 0 to 3 (WHO scale); Life expectancy greater than 3 months; * No other malignancy; * Adequate hepatic, renal, and bone marrow function (WBC≥3.0×109/L，ANC≥1.5×109/L，PLT≥80×109/L. Serum bilirubin≤1.5×the institutional upper limit of normal, ALT、ALP≤2.5×the institutional upper limit of normal, creatinine≤1.5×the institutional upper limit of normal); * Ability to understand objectives of the study, the study procedure, the pharmacological properties of the drug and possible adverse reactions and the willingness to sign a written informed consent. Exclusion Criteria: * Suffering from heart, liver, kidney disease or severe acute and chronic gastrointestinal diseases; * Pregnant or lactating women and be sensitive to drug; * Subjects are thought unsuitable for the study by investigators; * Inability to comply with protocol or study procedures in the opinion of the investigator; * Attending other clinical trials or attended other clinical trials 3 months ago.